Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alembic Q2 Gets Sartans Shot

Executive Summary

Continuing sartans crisis, new product launches in US help Alembic post strong Q2 performance despite slowdown in other markets.

You may also be interested in...



Jubilant Revenues Flat On LSI Decline

Jubilant reports higher second-quarter profits as it defers tax liability while revenues remain flat on the back of a decline in the LSI business and FDA action at two manufacturing units.

Jubilant Revenues Flat In Q2 On LSI Business Decline, FDA action

Jubilant reports higher second-quarter profits as it defers tax liability while revenues remain flat on the back of a decline in LSI business and FDA action at two manufacturing units.

US FDA Warns Torrent Over Losartan Process Validation, OOS Invalidation Failures

Warning letter stemming from global nitrosamine investigation raises new concerns about Indian manufacturer.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC126093

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel